Core Insights - Turnstone Biologics Corp. has appointed William Waddill to its Board of Directors, effective April 15, 2024, while Patrick Machado has stepped down from the Board [1][2] Group 1: Leadership Changes - William Waddill brings over 30 years of financial and operational expertise in the biotechnology sector and has held leadership roles in various organizations [2][3] - Patrick Machado has been recognized for his significant contributions to Turnstone over nearly six years [2] Group 2: Company Overview - Turnstone Biologics is focused on developing a novel Selected tumor-infiltrating lymphocyte (TIL) therapy aimed at treating solid tumors [4] - The company's lead clinical program, TIDAL-01, is currently in multiple Phase 1 studies targeting various cancers, including colorectal cancer and melanoma [4]

Company Summary - Annexon, Inc. (ANNX) closed at $6.17, reflecting a -0.96% change from the previous day's closing price, underperforming the S&P 500 which fell by 0.95% [1] - The stock has increased by 35.73% over the past month, outperforming the Medical sector's decline of 3.76% and the S&P 500's gain of 1.78% [1] - The upcoming earnings report is expected to show an EPS of -$0.32, representing a 38.46% increase compared to the same quarter last year [1] - Recent analyst forecast revisions for Annexon, Inc. are crucial as they indicate short-term business trends, with positive changes reflecting optimism about the company's profitability [1] Industry Summary - The Medical - Biomedical and Genetics industry is part of the broader Medical sector and currently holds a Zacks Industry Rank of 80, placing it in the top 32% of over 250 industries [2] - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), has shown that stocks rated 1 have delivered an average annual return of +25% since 1988 [2] - The top 50% rated industries outperform the bottom half by a factor of 2 to 1, indicating the importance of industry ranking in stock performance [3]

Investors might want to bet on Annexon, Inc. (ANNX) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Individual inv ...

Core Viewpoint - Annexon, Inc. (ANNX) has seen a 20.1% increase in share price over the past four weeks, closing at $7.17, with a mean price target of $14.42 indicating a potential upside of 101.1% [1] Price Targets and Analyst Consensus - The mean price target is based on six short-term estimates with a standard deviation of $8.04, indicating variability among analysts; the lowest estimate suggests an 18.6% increase, while the highest predicts a 318.4% surge to $30 [1] - Analysts have shown strong agreement in revising earnings estimates higher, with five estimates increasing in the last 30 days and no negative revisions, leading to a 14.2% increase in the Zacks Consensus Estimate [5] Analyst Behavior and Price Target Reliability - Analysts' price targets are often questioned for their reliability, as they may set overly optimistic targets influenced by business relationships, which can mislead investors [3] - A low standard deviation in price targets indicates a high degree of agreement among analysts regarding the stock's price movement, serving as a starting point for further research [4] Zacks Rank and Investment Potential - ANNX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting a strong potential upside [6]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39402 ANNEXON, INC. (Exact name of Registrant as specified in its Charter) Delaware 27-5414423 (State or other jurisdiction of incorp ...

Financial Position - Cash, cash equivalents, and short-term investments totaled approximately $260 million as of December 31, 2023, providing a runway into mid-2026[1] - Total current assets increased to $263,860,000 in December 2023 from $248,098,000 in December 2022, representing a growth of 6.9%[16] - Cash and cash equivalents rose significantly to $225,110,000, up from $140,020,000, marking an increase of 60.8% year-over-year[16] - Total liabilities decreased to $47,118,000 in December 2023 from $53,902,000 in December 2022, a reduction of 12.6%[16] - Total stockholders' equity increased to $250,556,000, up from $231,194,000, reflecting an increase of 8.4% year-over-year[16] - Accumulated deficit widened to $(572,499,000) from $(438,262,000), indicating an increase of 30.6%[16] - Accounts payable decreased to $5,487,000 from $7,416,000, a decline of 26.0%[16] - Accrued liabilities reduced to $10,235,000 from $13,448,000, a decrease of 24.5%[16] - Operating lease liabilities, current, increased to $2,165,000 from $1,316,000, an increase of 64.6%[16] - Additional paid-in capital rose to $823,029,000 from $669,780,000, an increase of 22.9%[16] - Property and equipment, net, decreased to $14,773,000 from $16,838,000, a decline of 12.3%[16] Research and Development - Research and development (R&D) expenses for Q4 2023 were $23.3 million, compared to $28.5 million in Q4 2022, while total R&D expenses for the year were $113.8 million, up from $112.5 million in 2022[9] - ANX005's pivotal Phase 3 trial in Guillain-Barré Syndrome (GBS) completed enrollment with 241 patients, and topline data is expected in Q2 2024[3] - ANX007's pivotal Phase 3 ARCHER II trial in Geographic Atrophy (GA) is expected to initiate in mid-2024, with a head-to-head trial against SYFOVRE planned for the second half of 2024[7] - ANX1502's proof-of-concept data is anticipated in the second half of 2024, following successful Phase 1 trials demonstrating safety and tolerability[6] - The company plans to submit Phase 2a data for ANX005 in Amyotrophic Lateral Sclerosis (ALS) for presentation at a medical conference later this year[6] Financial Performance - General and administrative (G&A) expenses for Q4 2023 were $6.7 million, down from $8.2 million in Q4 2022, with total G&A expenses for the year at $30.0 million, compared to $33.1 million in 2022[9] - Net loss for Q4 2023 was $27.9 million, a decrease from $34.4 million in Q4 2022, while the net loss for the full year was $134.2 million, compared to $141.9 million in 2022[9] - A successful financing of $125 million was completed in December 2023, extending the operating runway into mid-2026[3] Regulatory Designations - The company received Fast Track and orphan drug designations from the FDA for ANX005, and the EMA granted orphan drug designation based on positive meta-analysis results[3]

BRISBANE, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that it has granted inducement to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan. The equity award was approved on March 15, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4). The new non-executive emplo ...

Investors are always looking for stocks that are poised to beat at earnings season and Annexon, Inc. (ANNX) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.That is because Annexon is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicat ...

Annexon, Inc. (ANNX) , a clinical-stage company, is focused on developing novel therapies to treat patients suffering from serious complement-mediated autoimmune, neurodegenerative and ophthalmic disorders.The company has channeled its resources to prioritize the development of three candidates in its pipeline, such as ANX005 for Guillain-Barré syndrome, ANX007 for geographic atrophy (GA) and first-in-kind oral complement small molecule, and ANX1502 for several autoimmune indications.Over the past three mon ...

ANX005 Phase 3 Pivotal Data in Guillain-Barré Syndrome (GBS) On Track for First Half of 2024;Potential to be First Approved Treatment for GBS Patients in the U.S. ANX007 Global Pivotal Program in Geographic Atrophy (GA) to Initiate Mid-2024; First Pivotal Trial Using Vision Preservation as Primary Outcome Measure in GA Clinical Proof-of-Concept Study of ANX1502 First-in-Kind Oral Small Molecule Inhibitor of the Classical Pathway to Initiate in First Half of 2024 Recent Successful $125 Million Financing Exte ...